Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 447

Sort by

Sort Order Select

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Vaishali Bhardwaj, Zhi-Zhang Yang, Prithviraj Mukherjee, Rekha Mudappathi, Junewen Wang, Xinyi Tang, Jonas Paludo, Anne J. Novak, Patrizia Mondello, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2024-208966

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2024-200408

Published: 2024

Journal Articles

PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Steven I. Park, Stephen M. Ansell, Danielle Boselli, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, L. Elizabeth Budde, Andrew J Ness, Philip Bierman, Hun Ju Lee

Blood (2024) 144 (Supplement 1): 458.

https://doi.org/10.1182/blood-2024-202207

Published: 2024

Journal Articles

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Blood (2024) 144 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2024-194681

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 866.

https://doi.org/10.1182/blood-2024-199155

Published: 2024

Journal Articles

Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 2977.

https://doi.org/10.1182/blood-2024-208182

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Adi Zoref-Lorenz, Elliot J Cahn, Eric Mou, Yucai Wang, Matthew J. Maurer, Andrew L. Feldman, Bri J Negaard, Raphael Mwangi, Gilad Itchaki, Grzegorz S. Nowakowski, Thomas M. Habermann, Brian K. Link, Stephen M. Ansell, Anne J. Novak, Gaurav Goyal, Thomas E. Witzig, James R. Cerhan, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2024-210119

Published: 2024

Journal Articles

Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

Ariel Perez Perez, Nayef Abdel-Razeq, Tiba Al Sagheer, George Nahas, Jose Sandoval-Sus, Manny Alfonso, Carlos Silva, Syeda Saba Kareem, Katherine Tobon, Allison C. Rosenthal, Stephen M. Ansell, Yuliya PL Linhares, Muhamad Alhaj Moustafa, Hayder Saeed

Blood (2024) 144 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2024-208781

Published: 2024

Journal Articles

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Yucai Wang, Han W. Tun, Betsy R. LaPlant, Rebecca L. King, Ivana N. Micallef, Madiha Iqbal, Allison C. Rosenthal, Stephen M. Ansell, Jose C. Villasboas Bisneto, Arushi Khurana, Gita Thanarajasingam, Thomas M. Habermann, Javier L. Munoz, Paul J. Hampel, Patrick B. Johnston, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 580.

https://doi.org/10.1182/blood-2024-200206

Published: 2024

Journal Articles

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Jamie Johnston, Katie J. Doane, Wesley Waszak, Carolyn Flock, Arushi Khurana, Nina Logan, Nanci Hawley, Eyad Al-Hattab, Akeem R. Lewis, Jonathan Ticku, Amir Yosef, Stephen M. Ansell, Shaji Kumar, Sameer A. Parikh, Mithun V Shah, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 784.

https://doi.org/10.1182/blood-2024-205791

Published: 2024

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

Cytokine-Inducible SH2-Containing Protein (CISH) Is an Intracellular Immune Checkpoint That Controls T Regulatory Cells in Splenic Marginal Zone Lymphoma

Xinyi Tang, Zhi-Zhang Yang, Yue Yu, Xiaosheng Wu, Vaishali Bhardwaj, Prithviraj Mukherjee, Patrizia Mondello, Hyojin Kim, Anne J. Novak, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2024-208187

Published: 2024

NARROW

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Cytokine-Inducible SH2-Containing Protein (CISH) Is an Intracellular Immune Checkpoint That Controls T Regulatory Cells in Splenic Marginal Zone Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only